Scancell Holdings plc is a biotechnology business based in the UK. Scancell Holdings shares (SCLP.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Its last market close was 10.85p – a decrease of 8.31% over the previous week. Scancell Holdings employs 22 staff and has a market cap (total outstanding shares value) of £136.5 million.
Since the stock market crash in March caused by coronavirus, Scancell Holdings's share price has had significant positive movement.
Its last market close was 10.85p, which is 40.55% up on its pre-crash value of 6.45p and 158.33% up on the lowest point reached during the March crash when the shares fell as low as 4.2001p.
If you had bought £1,000 worth of Scancell Holdings shares at the start of February 2020, those shares would have been worth £580.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,446.67.
|Latest market close||10.85p|
|52-week range||4.1118p - 18.25p|
|50-day moving average||12.3586p|
|200-day moving average||10.5322p|
|Wall St. target price||55p|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||-1.5p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 month (2020-12-23)||-34.24%|
|3 months (2020-10-22)||-23.86%|
|Gross profit TTM||£0|
|Return on assets TTM||-43.79%|
|Return on equity TTM||-64.83%|
|Market capitalisation||£136.5 million|
TTM: trailing 12 months
We're not expecting Scancell Holdings to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Scancell Holdings's shares were split on a 10:1 basis on 26 July 2011. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Scancell Holdings shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Scancell Holdings shares which in turn could have impacted Scancell Holdings's share price.
Over the last 12 months, Scancell Holdings's shares have ranged in value from as little as 4.1118p up to 18.25p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Scancell Holdings's is 0.0615. This would suggest that Scancell Holdings's shares are less volatile than average (for this exchange).
Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.